Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

1.

Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

Shillingford JM, Piontek KB, Germino GG, Weimbs T.

J Am Soc Nephrol. 2010 Mar;21(3):489-97. doi: 10.1681/ASN.2009040421. Epub 2010 Jan 14.

PMID:
20075061
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus.

Stayner C, Shields J, Slobbe L, Shillingford JM, Weimbs T, Eccles MR.

Nephrology (Carlton). 2012 Nov;17(8):739-47. doi: 10.1111/j.1440-1797.2012.01639.x.

PMID:
22725947
[PubMed - indexed for MEDLINE]
3.

Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.

Leonhard WN, van der Wal A, Novalic Z, Kunnen SJ, Gansevoort RT, Breuning MH, de Heer E, Peters DJ.

Am J Physiol Renal Physiol. 2011 May;300(5):F1193-202. doi: 10.1152/ajprenal.00419.2010. Epub 2011 Feb 23.

PMID:
21345977
[PubMed - indexed for MEDLINE]
Free Article
4.

Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease.

Novalic Z, van der Wal AM, Leonhard WN, Koehl G, Breuning MH, Geissler EK, de Heer E, Peters DJ.

J Am Soc Nephrol. 2012 May;23(5):842-53. doi: 10.1681/ASN.2011040340. Epub 2012 Feb 16.

PMID:
22343118
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.

Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, Somlo S, Strazzabosco M.

Hepatology. 2010 May;51(5):1778-88. doi: 10.1002/hep.23511.

PMID:
20131403
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.

Zafar I, Ravichandran K, Belibi FA, Doctor RB, Edelstein CL.

Kidney Int. 2010 Oct;78(8):754-61. doi: 10.1038/ki.2010.250. Epub 2010 Aug 4.

PMID:
20686448
[PubMed - indexed for MEDLINE]
7.

Loss of oriented cell division does not initiate cyst formation.

Nishio S, Tian X, Gallagher AR, Yu Z, Patel V, Igarashi P, Somlo S.

J Am Soc Nephrol. 2010 Feb;21(2):295-302. doi: 10.1681/ASN.2009060603. Epub 2009 Dec 3.

PMID:
19959710
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5' end of Pkd1.

Starremans PG, Li X, Finnerty PE, Guo L, Takakura A, Neilson EG, Zhou J.

Kidney Int. 2008 Jun;73(12):1394-405. doi: 10.1038/ki.2008.111. Epub 2008 Apr 2.

PMID:
18385665
[PubMed - indexed for MEDLINE]
9.

Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways.

Happé H, Leonhard WN, van der Wal A, van de Water B, Lantinga-van Leeuwen IS, Breuning MH, de Heer E, Peters DJ.

Hum Mol Genet. 2009 Jul 15;18(14):2532-42. doi: 10.1093/hmg/ddp190. Epub 2009 Apr 28.

PMID:
19401297
[PubMed - indexed for MEDLINE]
Free Article
10.

Pkd1 inactivation induced in adulthood produces focal cystic disease.

Takakura A, Contrino L, Beck AW, Zhou J.

J Am Soc Nephrol. 2008 Dec;19(12):2351-63. doi: 10.1681/ASN.2007101139. Epub 2008 Sep 5.

PMID:
18776127
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.

Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T.

Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5466-71. Epub 2006 Mar 27.

PMID:
16567633
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Elevated TGFbeta-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease.

Hassane S, Leonhard WN, van der Wal A, Hawinkels LJ, Lantinga-van Leeuwen IS, ten Dijke P, Breuning MH, de Heer E, Peters DJ.

J Pathol. 2010 Sep;222(1):21-31. doi: 10.1002/path.2734.

PMID:
20549648
[PubMed - indexed for MEDLINE]
13.

Ectopic expression of Cux1 is associated with reduced p27 expression and increased apoptosis during late stage cyst progression upon inactivation of Pkd1 in collecting ducts.

Paul BM, Vassmer D, Taylor A, Magenheimer L, Carlton CG, Piontek KB, Germino GG, Vanden Heuvel GB.

Dev Dyn. 2011 Jun;240(6):1493-501. doi: 10.1002/dvdy.22625. Epub 2011 Apr 4.

PMID:
21465620
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP.

Nephrol Dial Transplant. 2006 Mar;21(3):598-604. Epub 2005 Oct 12.

PMID:
16221708
[PubMed - indexed for MEDLINE]
Free Article
15.

Folate-conjugated rapamycin slows progression of polycystic kidney disease.

Shillingford JM, Leamon CP, Vlahov IR, Weimbs T.

J Am Soc Nephrol. 2012 Oct;23(10):1674-81. Epub 2012 Aug 2.

PMID:
22859856
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.

Renken C, Fischer DC, Kundt G, Gretz N, Haffner D.

Nephrol Dial Transplant. 2011 Jan;26(1):92-100. doi: 10.1093/ndt/gfq384. Epub 2010 Jul 7.

PMID:
20615907
[PubMed - indexed for MEDLINE]
Free Article
17.

Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1.

Jiang ST, Chiou YY, Wang E, Lin HK, Lin YT, Chi YC, Wang CK, Tang MJ, Li H.

Am J Pathol. 2006 Jan;168(1):205-20.

PMID:
16400024
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Apoptosis in polycystic kidney disease.

Goilav B.

Biochim Biophys Acta. 2011 Oct;1812(10):1272-80. doi: 10.1016/j.bbadis.2011.01.006. Epub 2011 Jan 15. Review.

PMID:
21241798
[PubMed - indexed for MEDLINE]
Free Article
19.

Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.

Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, Wallace DP, Weimbs T, Wüthrich RP.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1312-29. doi: 10.2215/CJN.01360210. Epub 2010 May 24. Review.

PMID:
20498248
[PubMed - indexed for MEDLINE]
Free Article
20.

The mTOR pathway is activated in human autosomal-recessive polycystic kidney disease.

Becker JU, Opazo Saez A, Zerres K, Witzke O, Hoyer PF, Schmid KW, Kribben A, Bergmann C, Nürnberger J.

Kidney Blood Press Res. 2010;33(2):129-38. doi: 10.1159/000314380. Epub 2010 May 12.

PMID:
20460933
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk